To read more on this topic click here.
Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs
Author: Simge Eva DoganPublished: 7 November 2018
Prep: Cook: Serves:
Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.
The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.
Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”
For more information on Parkinson’s treatments please visit Parkinson’s Europe website
Share this story
#UniteForParkinsons around the world
The 2018 #UniteForParkinsons campaign reaches 8 millionREAD MORE
Young-onset Parkinson’s disease: the challenges and treatment options
Register for this free, hour-long webinarREAD MORE
Mother of schoolgirl who met Sir Billy Connolly “blown away” by daughter’s selflessness
Abby has raised more than UK £1,200 for Parkinson’sREAD MORE